Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome by Luotola, Kari et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=igye20
Download by: [85.76.164.133] Date: 06 July 2017, At: 11:24
Gynecological Endocrinology
ISSN: 0951-3590 (Print) 1473-0766 (Online) Journal homepage: http://www.tandfonline.com/loi/igye20
Testosterone is associated with insulin resistance
index independently of adiposity in women with
polycystic ovary syndrome
Kari Luotola, Terhi T Piltonen, Johanna Puurunen, Laure C Morin-Papunen &
Juha S Tapanainen
To cite this article: Kari Luotola, Terhi T Piltonen, Johanna Puurunen, Laure C Morin-Papunen &
Juha S Tapanainen (2017): Testosterone is associated with insulin resistance index independently
of adiposity in women with polycystic ovary syndrome, Gynecological Endocrinology, DOI:
10.1080/09513590.2017.1342793
To link to this article:  http://dx.doi.org/10.1080/09513590.2017.1342793
View supplementary material 
Published online: 05 Jul 2017.
Submit your article to this journal 
View related articles 
View Crossmark data
ORIGINAL ARTICLE
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ABSTRACT
Objective: To study the associations between androgens, glucose homeostasis, inflammation and statin
treatment in women with polycystic ovary syndrome (PCOS).
Design and methods: Oral glucose tolerance tests, androgens, hs-CRP and interleukin-1 receptor antag-
onist (IL-1Ra) were analyzed at baseline and after 6months of atorvastatin (20mg/d) or placebo treatment
in 27 women with PCOS.
Results: Testosterone associated with insulin resistance measured with ISIMatsuda independently of BMI,
age and SHBG concentrations and the full model, including IL-1Ra, hs-CRP and HDL-C, also showed inde-
pendency of BMI and waist circumference (p .042). Free androgen index (FAI) associated with ISIMatsuda
independently of adiposity (p .025) but in the full model with waist circumference the association was
insignificant. ISIMatsuda decreased with testosterone >1.2 nmol/l compared with lower levels at baseline
(p¼ .043) and at six months (p¼ .003). Accordingly, 30-minute insulin levels were increased with moder-
ately elevated testosterone independently of adiposity (p .046). Increased fasting glucose and AUC insu-
lin associated with statin treatment independently of adiposity and the associations attenuated after
adjusting for testosterone.
Conclusions: Moderately elevated testosterone concentrations together with obesity-related inflammatory
factors modify glucose homeostasis by increasing insulin resistance and early insulin secretion.
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Introduction
Glucose metabolism disorders are more common in hyperandro-
genic women with polycystic ovary syndrome (PCOS) compared
with the nonhyperandrogenic phenotype (polycystic ovaries in
ultrasonography and the presence of chronic oligo-anovulation)
[1]. During early adulthood, women with PCOS show a propen-
sity to experience excessive weight gain and dyslipidemia [2], and
later, in life, they also present with other cardiovascular risk fac-
tors, such as hypertension and metabolic syndrome [3,4].
Therefore, medical therapy of hyperlipidemia with 3-hydroxy-3-
methylglutaryl-CoA reductase inhibitors (statins) has been sug-
gested in the prevention of cardiovascular disease in women with
PCOS [5]. Moreover, as statins have been proposed to inhibit
androgen synthesis [6,7], their use might have therapeutically sig-
nificant advantages. Recently we found in a prospective, placebo-
controlled study that despite substantial benefits of statins in
improving lipid profiles, treatment with atorvastatin for six
months in women with PCOS was followed by only a marginal
change in androgen synthesis and resulted in the impairment of
glucose homeostasis and reduced insulin sensitivity [8].
Furthermore, statins seem to increase the risk of development of
type-2 diabetes (T2DM) [9].
Increased inflammatory activity is common in women with
PCOS [1]. The (pro-inflammatory) interleukin-1 (IL-1) ligands
are known to be important mediators of metabolic disturbances
and the natural anti-inflammatory IL-1 receptor antagonist
(IL-1Ra) increases with adiposity and has protective effects on
insulin secretion in pancreatic b-cells [10]. IL-1Ra reflects inflam-
matory activity and appears to be a useful parameter that has
been reported to be associated with glucose tolerance and dis-
posal in women with PCOS [11]. Furthermore, IL-1Ra has been
shown to independently predict the development of T2DM
[12,13]. In the present study, we hypothesized that androgen
excess and increased inflammation decrease insulin sensitivity
and that androgens may have interactions with inflammatory fac-
tors in adipose tissue.
Subjects and methods
Subjects
Our randomized, double-blind, placebo-controlled follow-up
study involved 38 women (aged 29–50 years) with PCOS and
without a history of impaired glucose tolerance (IGT) or T2DM.
The detailed study design of this complementary study has been
previously reported [8]. The subjects used either atorvastatin
(Pfizer Inc., 20mg/day) or placebo for 6months (ClinicalTrials.gov
NCT01072097). Twenty-eight women completed the study
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protocol (n¼ 15 in the atorvastatin group; n¼ 13 in the placebo
group) and 27 subjects aged 29–47 years were included in the anal-
yses. The diagnosis of PCOS was based on the Rotterdam consen-
sus criteria [1] except for the diagnosis of polycystic ovaries in
ultrasonography, where more stringent criteria were used [14].
Biochemical or clinical hyperandrogenism was present in 48% of
the subjects. Oral contraceptives and other medication affecting
glucose or steroid metabolism were interrupted at least two
months before the study. The study protocols were approved by
the Ethics Committee of Oulu University Hospital. All subjects
signed a written informed consent document.
Glucose tolerance tests
Two-hour oral glucose tolerance tests (OGTTs) were performed in
27 PCOS cases, and at baseline, four women were found to have
IGT or T2DM based on the results. The degree of insulin sensitiv-
ity was measured by using HOMA-IR or the Matsuda index
(ISIMatsuda) [15]. Incremental area under the curve (AUC) values
were calculated in OGTTs. Insulin sensitivity was also assessed by
using the intravenous glucose tolerance test (SiIVGTT) [16].
Assays
Serum samples were analyzed for testosterone by using Agilent
triple-quadrupole 6410 liquid chromatography-mass spectrometry
equipment with an electrospray ionization source operating in
positive-ion mode (Agilent Technologies), with a sensitivity of
0.03 nmol/l. Multiple reaction monitoring was used to quantify
testosterone by using trideuterated testosterone (d3-testosterone)
with the following transitions: mass to charge ratios 289.2 to 97
and 289.2 to 109 for testosterone and 292.2 to 97 and 292.2 to
109 for d3-testosterone. Serum concentrations of androstenedione,
dehydroepiandrosterone sulfate (DHEAS) and sex-hormone-bind-
ing globulin (SHBG) were analyzed by chemiluminometric immu-
noassays, with sensitivities of 1.0 nmol/l for androstenedione,
0.08lmol/l for DHEAS and 0.02 nmol/l for SHBG (Immulite
2000; Siemens Healthcare Diagnostics). The free androgen index
(FAI) was calculated by using the following equation: testosterone
(nmol/l) 100/SHBG (nmol/l). Levels of high-density lipoprotein
cholesterol (HDL-C) (Advia 1800; Siemens Healthcare diagnos-
tics), C-reactive protein (hs-CRP) (BN ProSpec; Siemens
Healthcare diagnostics) and IL-1Ra (QuantikineV
R
ELISA kits R&D
Systems) were measured at baseline and at six months.
Statistical methods
Correlation analyses were performed by using Pearson’s coeffi-
cients. Linear regression analysis was used to study androgen lev-
els and glucose homeostasis at baseline and to study associations
with glucose homeostasis after six months of follow-up. Levels of
IL-1Ra and glucose homeostasis parameters were analyzed by
using independent t-test. Statistical significance was set at p< .05.
Statistical analyses were performed by using IBM SPSS Statistics
Version 22 software.
Results
Associations between androgens and glucose homeostasis
parameters
Demographic data on the women with PCOS are shown in
Supplemental Table. Testosterone levels at baseline correlated
significantly with insulin secretion during OGTTs (30-min insu-
lin: r¼ 0.421, p¼ .029; 1-h insulin: r¼ 0.421, p¼ .029 and AUC
insulin: r¼ 0.412, p¼ .033). Accordingly, insulin secretion corre-
lated with FAI values (30-min insulin: r¼ 0.671, p< .001; 1-h
insulin: r¼ 0.633, p< .001 and AUC insulin: r¼ 0.653, p< .001)
and with SHBG (30-min insulin: r¼0.422, p¼ .028; 1-h insu-
lin: r¼0.406, p¼ .036 and AUC insulin: r¼0.419, p¼ .029).
FAI and SHBG levels correlated significantly also with other
OGTT-derived parameters (data not shown). Concentrations of
testosterone, androstenedione and DHEAS showed non-signifi-
cant correlations with OGTT glucose and C-peptide levels.
At baseline the FAI correlated negatively with insulin sensitiv-
ity measured by the way of ISIMatsuda (r¼0.585, p¼ .001),
HOMA-IR (r¼ 0.582, p¼ .001) and SiIVGTT (r¼0.446,
p¼ .020) in women with PCOS. Similarly, SHBG levels correlated
with ISIMatsuda (r¼ 0.572, p¼ .002) and HOMA-IR (r¼0.488,
p¼ .010). ISIMatsuda correlated negatively with HOMA-IR
(r¼0.756, p< .001) and positively with SiIVGTT (r¼ 0.717,
p< .001). HOMA-IR correlated negatively with SiIVGTT
(r¼0.605, p¼ .001).
ISIMatsuda decreased with increasing serum testosterone and
FAI levels independently of BMI at baseline in women with
PCOS (Table 1(a)). Multivariate analysis including all covariates
(age, BMI, testosterone, SHBG, IL-1Ra, hs-CRP and HDL-C)
showed associations between ISIMatsuda and testosterone
(p¼ .031) and FAI (p¼ .025) and were significant in full-model
analysis (testosterone: r2¼ 0.705 and FAI: r2¼ 0.688) (Table
1(a)). When using waist circumference as a covariate in the full
model, ISIMatsuda decreased with increasing testosterone levels
(p¼ .040). ISIMatsuda decreased with increasing FAI (p¼ .020)
independently of waist circumference and age, and a nonsignifi-
cant association was seen in the full model (p¼ .054).
Increased OGTT 30-min insulin levels were associated with
increased testosterone levels (p¼ .046) and FAI values (p¼ .028)
in the full model including BMI and in the model including age,
BMI and/or SHBG (Table 1(b)). Adjusting for waist circumfer-
ence, age and SHBG showed that the increased 30-min insulin
levels were associated positively with testosterone levels
(p¼ .043). The FAI was associated with 30-min insulin independ-
ently of age and waist circumference (p¼ .028) and showed non-
significant association in the full model (p¼ .054).
The mean serum testosterone concentration in women with
PCOS at the beginning of the study was 1.19 nmol/l. The 10 sub-
jects with levels above this value displayed decreased insulin sen-
sitivity (ISIMatsuda values) when compared with those with
testosterone levels below the mean (mean [SD]: 4.50 [2.68] vs.
7.20 [3.43], p¼ .043, respectively). Accordingly, OGTT 30-min
insulin levels were increased in subjects with higher testosterone
levels (115.7 [74.1] mU/l vs. 48.9 [35.0] mU/l, p¼ .021). After 6
months’ follow-up, insulin sensitivity (ISIMatsuda) was still
decreased in the 10 subjects with testosterone above 1.19 nmol/l
compared with the levels in 17 subjects with testosterone under
this limit (3.10 [2.10] vs. 7.80 [5.21], p¼ .003) and, accordingly,
30-min insulin levels were increased (146.7 [88.6] mU/l vs. 70.3
[55.2] mU/l, p¼ 0.010).
Association of IL-1Ra levels with FAI and SHBG
IL-1Ra correlated with FAI values (r¼ 0.415, p¼ .032) and
SHBG concentrations (r¼0.454, p¼ .017) at baseline and after
adjusting for age the correlations remained significant (FAI:
b¼ 0.535, p¼ .018 and SHBG: b¼0.453, p¼ .020). IL-1Ra lev-
els in women with PCOS undergoing atorvastatin treatment
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(402.4 [273.2] pg/ml) were comparable with the placebo group
(280.2 [190.6] pg/ml, p¼ .19) at baseline. Accordingly, at six
months, IL-1Ra levels in atorvastatin group (430.4 [375.9] pg/ml)
were comparable with the placebo group (242.8 [103.7] pg/ml,
p¼ .093).
Glucose homeostasis at 6months
Increased baseline IL-1Ra levels were associated positively with
1-h glucose levels at six months in women with PCOS independ-
ently of age, waist circumference and intervention (atorvastatin
or placebo), as shown in Table 2(a). Levels of IL-1Ra were also
associated with 1-h glucose levels at six months in the full model
that included intervention, age, waist circumference, testosterone,
SHBG, HDL-C and hs-CRP (p¼ .018) but was nonsignificant
after adjusting for BMI.
Atorvastatin treatment, IL-1Ra and waist circumference were
associated with increased AUC insulin values (Table 2(b)). After
adjusting for testosterone (p¼ .140) or FAI the association
between atorvastatin treatment and AUC insulin became non-sig-
nificant. Atorvastatin treatment was also associated with
increased fasting glucose independently of BMI and age, but
the association disappeared after adjustment for testosterone
(Table 3). Atorvastatin treatment was associated positively with
fasting glucose after adjustment for waist circumference and age
(p¼ .014) and adjusting further for testosterone showed attenu-
ation of the significance (p¼ .040). Models with atorvastatin, tes-
tosterone, SHBG, age and adiposity (BMI or waist
circumference) and the full models showed that baseline testos-
terone levels were solely associated positively with testosterone
levels at six months (p< .001).
Discussion
The present study shows evidence of an association between tes-
tosterone levels and FAI and decreased insulin sensitivity index
values, independently of BMI and waist circumference in women
with PCOS. Statin treatment was positively associated with fast-
ing glucose and AUC insulin values independently of adiposity,
and the associations attenuated after adjusting for testosterone.
Increased early-phase insulin secretion has previously been
reported to reflect increased functional capacity of b-cells
Table 2a. Associations of 1-h glucose level (a) and AUC insulin (b) in women with PCOS at 6months.
b-coefficient (with p value) for 1-h glucose
Model Atorvastatin Age IL-1Ra Waist FAI SHBG HDL-C CRP r2
1 0.120 (0.39) 0.150 (0.29) 0.512 (0.013) 0.305 (0.12) 0.634
2 0.035 (0.85) 0.255 (0.22) 0.489 (0.021) 0.244 (0.25) 0.186 (0.48) 0.643
3 0.093 (0.51) 0.163 (0.25) 0.487 (0.021) 0.238 (0.24) 0.184 (0.26) 0.657
4 0.109 (0.44) 0.093 (0.54) 0.592 (0.010) 0.330 (0.097) 0.176 (0.34) 0.650
5 0.122 (0.40) 0.150 (0.30) 0.514 (0.016) 0.309 (0.14) 0.013 (0.93) 0.634
Model 1 was adjusted for atorvastatin therapy/placebo, age, IL-1 receptor antagonist (IL-1Ra) and waist circumference. Models from 2 to 5 were further adjusted for
FAI, SHBG, HDL-C and CRP.
Table 1. Multivariate analysis of baseline insulin resistance (IR) indices (a) and OGTT insulin levels (b) in women with PCOS. The models were adjusted for age, BMI,
sex hormone-binding globulin (SHBG) and testosterone, and also for the free androgen index (FAI) together with age and BMI.
a
b-coefficient (with p value) for IR index
IR index BMI SHBG testosterone FAI r2
ISIMatsuda 0.589, 0.529 (0.001, 0.002) 0.221 (0.16) 0.332 (0.042) 0.449 (0.016) 0.662, 0.660
HOMA-IR 0.870, 0.769 (0.001) 0.020 (0.87) 0.073 (0.56) 0.143 (0.31) 0.783, 0.789
SiIVGTT 0.598, 0.450 (0.007, 0.030) 0.036 (0.86) 0.266 (0.20) 0.316 (0.18) 0.412, 0.414
IVGTT: intravenous glucose tolerance test.
b
b-coefficient (with p value) for insulin levels
OGTT insulin BMI SHBG testosterone FAI r2
fasting insulin 0.874, 0.798 (0.001) 0.021 (0.86) 0.076 (0.53) 0.147 (0.28) 0.794, 0.800
30-min insulin 0.624, 0.449 (0.009) 0.041 (0.81) 0.371 (0.038) 0.481 (0.015) 0.595, 0.619
1-h insulin 0.695, 0.569 (0.001) 0.016 (0.92) 0.303 (0.069) 0.300 (0.11) 0.641, 0.625
2-h insulin 0.763, 0.644 (0.001) 0.061 (0.69) 0.182 (0.25) 0.210 (0.24) 0.659, 0.656
AUC insulin 0.721, 0.584 (0.001) 0.017 (0.91) 0.289 (0.070) 0.321 (0.074) 0.668, 0.664
Table 2b.
b-coefficient (with p value) for AUC insulin
Model Atorvastatin Age IL-1Ra Waist FAI SHBG HDL-C CRP r2
1 0.294 (0.021) 0.145 (0.24) 0.379 (0.031) 0.409 (0.020) 0.727
2 0.235 (0.15) 0.72 (0.68) 0.363 (0.044) 0.367 (0.055) 0.130 (0.57) 0.731
3 0.288 (0.029) 0.143 (0.26) 0.372 (0.040) 0.394 (0.035) 0.040 (0.78) 0.728
4 0.30 (0.021) 0.111 (0.41) 0.331 (0.082) 0.393 (0.028) 0.105 (0.51) 0.733
5 0.270 (0.033) 0.147 (0.22) 0.361 (0.038) 0.354 (0.045) 0.164 (0.21) 0.748
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together with decreased glucose disposal in obese women with
PCOS (17). In the present study, increased 30-min insulin levels
in OGTTs were associated with testosterone levels independently
of adiposity, suggesting that androgens may alter insulin sensitiv-
ity. This was also supported by the observation of a decreased
insulin sensitivity index and increased 30-min insulin levels in
subjects with high (>1.2 nmol/l) versus low (<1.2 nmol/l) testos-
terone levels. The relatively low sample size and number of varia-
bles in the full model limit to draw detailed presumptions about
the role of inflammatory factors. Adipose tissue plays a central
role in subclinical inflammation, which has been observed in
cases of PCOS [1,11] and is associated with abdominal obesity
and metabolic disturbances [18]. The findings of the present
study are further supported by the results of a recent study in
which adipocyte morphology, increased inflammation and large
waist circumference were associated with insulin resistance in
women with PCOS [19]. We also found that increased levels of
IL-1Ra, a natural anti-inflammatory factor reflecting inflamma-
tory activity, correlated with increased FAI values independently
of age in women with PCOS and predicted 1-h glucose levels at
six months independently of abdominal adiposity. These results
further strengthen the roles of androgens and inflammatory fac-
tors in insulin resistance and thereby long-term health conse-
quences in women with PCOS.
Atorvastatin treatment was associated positively with fasting
glucose levels and AUC insulin at six months independently of
adiposity, and the association weakened after adjusting for serum
testosterone levels. This suggests a possible role of androgens in
altered glucose homeostasis during statin therapy. However, the
mechanisms remain unclear, as in one of our previous studies
only DHEAS levels decreased [8] and androgen metabolism may
be affected by the interaction of glucose, insulin and immune
factors during atorvastatin treatment. However, some other
short-term studies have revealed decreased testosterone levels
during atorvastatin treatment [20–26] and it has been suggested
that the effect of statins on androgen and glucose metabolism is
time-, dose- and drug-dependent. In line with this, in the present
study, women with testosterone levels >1.2 nmol/l exhibited
greater early insulin responses and decreased insulin sensitivity
index values compared with women with testosterone levels
<1.2 nmol/l, suggesting that even moderately increased testoster-
one levels (within the normal range) may alter insulin sensitivity.
Although testosterone levels were associated with insulin sen-
sitivity when assessed by means of ISIMatsuda, there were no sig-
nificant associations with HOMA-IR or SiIVGTT. This may be
explained by the notion that insulin sensitivity indices reflect the
situation in different body compartments, that is, whole body,
hepatic and peripheral tissues [15]. ISIMatsuda is based on OGTTs
and better reflects whole-body insulin sensitivity, whereas
HOMA-IR reflects hepatic and SiIVGTT peripheral tissues. The
results of earlier studies involving the hyperinsulinemic euglyce-
mic clamp technique are in line with our results, showing
associations between androgens and insulin resistance measured
by ISIMatsuda [27,28]. Moreover, the present study showed that
the FAI robustly correlated with all indices of insulin resistance
in unadjusted analyses. Multivariate analysis of SiIVGTT showed
substantially lower r2 values compared with analyzes of ISIMatsuda
and HOMA-IR in women with PCOS as regards the association
between testosterone levels and insulin sensitivity. It is therefore
possible that SiIVGTT captures different components of changes in
insulin sensitivity compared with ISIMatsuda and HOMA-IR, as
recently suggested [29]. However, in our study, ISIMatsuda corre-
lated almost identically with HOMA-IR and SiIVGTT in
unadjusted analyses.
The present study shows that increased testosterone levels and
FAI values in women with PCOS are associated with decreased
insulin sensitivity index values and increased early insulin secre-
tion, independently of adiposity. Moreover, hyperandrogenemia
assessed by way of the FAI correlated positively with IL-1Ra lev-
els, underlining the role of androgens and inflammatory factors
in glucose homeostasis. This study shows evidence that moder-
ately elevated testosterone levels, within the normal range, may
alter insulin sensitivity in women with PCOS.
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